A Review of Dose-dense Temozolomide Alone and in Combination with Bevacizumab in Patients with First Relapse of Glioblastoma
2012 (English)In: Anticancer Research, ISSN 0250-7005, Vol. 32, no 9, 4001-4006 p.Article, review/survey (Refereed) Published
Treatment of patients with glioblastoma improved dramatically when concomitant and adjuvant temozolomide was added to external radiation therapy. The addition of this new treatment schedule as well as the improvements in individually-tailored radiation treatment, has resulted in a larger proportion of patients being fit for further treatment after first relapse. One of the most interesting combinations that have started to become part of the therapeutic arsenal in the daily clinic is dose-dense temozolomide in combination with bevacizumab. We reviewed and compiled the literature concerning the present topic based on a search of the PubMed database (http://www.ncbi.nlm.nih.gov/pubmed/) for the years between 1995 and 2011. The clinical studies that have been performed are small and divergent, making it difficult to grade the scientific evidence for the combinatorial treatment of dose-dense temozolomide and bevacizumab. However, the available studies and the experience we have at our departments suggest that this combination is of interest for glioblastoma patients experiencing first relapse. More randomized clinical trials are needed in order to establish the standard of treatment at first relapse in patients with glioblastoma.
Place, publisher, year, edition, pages
2012. Vol. 32, no 9, 4001-4006 p.
Dose-dense, temozolomide, bevacizumab, glioblastoma, relapse, review
Cancer and Oncology
IdentifiersURN: urn:nbn:se:umu:diva-61196ISI: 000309243200054OAI: oai:DiVA.org:umu-61196DiVA: diva2:566652